Related Experiment Videos
The interaction of hemicholinium-3 (HC-3) with cholinomimetics and atropine
Insights
HC-3 inhibits cardiac responses to acetylcholine and carbachol through a noncompetitive mechanism. This compound interacts at a distinct regulatory site, affecting agonist and antagonist binding affinities in atrial preparations.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Acetylcholine and carbachol are key neurotransmitters influencing cardiac function.
- Understanding drug interactions at the molecular level is crucial for cardiovascular drug development.
Purpose of the Study:
- To investigate the mechanism of antagonism by HC-3 on cholinomimetic-induced cardiac responses.
- To elucidate the interaction site of HC-3 in atrial preparations.
Main Methods:
- Experiments were conducted on spontaneously beating and electrically driven guinea pig atrial preparations.
- Dose-response curves were analyzed for acetylcholine and carbachol in the presence of varying HC-3 concentrations.
- Antagonism was assessed for both agonists and the competitive antagonist atropine.
Main Results:
- HC-3 inhibited negative inotropic responses to acetylcholine and carbachol in a noncompetitive manner.
- The antagonism was concentration-dependent and affected agonist and antagonist affinities.
- HC-3 showed greater antagonism towards carbachol than acetylcholine.
Conclusions:
- HC-3 acts as a noncompetitive antagonist by interacting with a regulatory site distinct from cholinomimetic binding sites.
- This interaction modulates the affinities of both agonists and competitive antagonists.
- The findings provide insights into novel mechanisms of cardiovascular drug action.
Abstract:
In either spontaneously beating or electrically driven atrial preparations of the guinea pig HC-3 (0.01-1 mM) inhibited negative inotropic responses to acetylcholine or carbachol. Although there was a parallel rightwards shift of the log concentration--response curves for acetylcholine or carbachol and no depression of the maximal response the type of antagonism was not competitive as the relationship between dose ratio -- 1) and concentration of HC-3 was not linear over the whole range investigated. A lesser degree of antagonism than expected for a competitive antagonist was observed with higher concentrations of HC-3. HC-3 was a more effective antagonist of responses to carbachol than to acetylcholine and pretreatment of animals with dyflos did not modify this difference. In addition, HC-3 was found to antagonize the inhibitory action of atropine on responses to acetylcholine and to a lesser extent carbachol. The results can be explained in terms of the interaction of HC-3 at a regulatory site distinct from the binding sites for cholinomimetics and atropinics. Interaction of HC-3 at the postulated site produces a noncompetitive antagonism of both agonists and competitive antagonists by modifying the affinities of the compounds for their respective binding sites.